PRODUCT DETAILS VIEW ALL PRODUCTS

Pulmocef CV Tablets (Cefuroxime axetil + Clavulanate Potassium)

  • Each tablet contains Cefuroxime axetil 250 mg/ 500 mg + Clavulanic acid 62.5 mg/ 125 mg.
  • Indicated for adult patients with infection caused susceptible microorganisms including S. aureus viz UTI, upper and lower RTI and gonococcal urethritis.
  • Cefuroxime has bactericidal activity against a wide range of common pathogens, including beta-lactamase producing strains. The bactericidal action of cefuroxime results from inhibition of cell wall synthesis by binding to essential target proteins. Clavulanic acid competitively and irreversibly inhibits a wide variety of beta-lactamases, commonly found in micro-organisms resistant to penicillins and cephalosporins. Binding and irreversibly inhibiting the beta-lactamase results in a restauration of the antimicrobial activity of beta-lactam antibiotics against lactamase-secreting-resistant bacteria.
  • Adults and Adolescents (13 years and older): Pharyngitis/tonsillitis (mild to moderate): 250 mg every 12 hours for 10 days. Acute bacterial maxillary sinusitis (mild to moderate):250 mg every 12 hours for 10 days. Acute bacterial exacerbations of chronic bronchitis (mild to moderate):250 or 500 mg every 12 hours for 10 days. Secondary bacterial infections of acute bronchitis: 250 or 500 mg every 12 hours for 5 to 10 days. Uncomplicated skin and skin-structure infections: 250 or 500 mg every 12 hours for 10 days. Uncomplicated urinary tract infections: 250 or 500 mg every 12 hours for 7 to 10 days. Pediatric Patients younger than 13 years (who can swallow tablets whole): Acute bacterial otitis media: 250 mg every 12 hours for 10 days. Acute bacterial maxillary sinusitis: 250 mg every 12 hours for 10 days.
  • Contraindicated in patients with a known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).
  • Before therapy with Pulmocef is instituted, careful inquiry should be made to determine whether the patient has any previous hypersensitivity reactions to cephalosporins. C. difficle associated diarrhea is reported with the use of antibacterial agents including cefuroxime. As with other antibiotics, prolonged use of Pulmocef may result in overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. Should be used in caution in individuals with a history of gastro-intestinal disease.
  • There are no adequate and well-controlled studies in human pregnancy. This product should only be used in pregnancy if considered essential by the physician. Since cefuroxime is excreted into human milk, caution should be exercised when Pulmocef is administered to a nursing women. Safety and effectiveness in pediatric patients has not been established.
  • Drugs that reduce gastric acidity may result in a lower bioavailability of Pulmocef CV Tablets compared with that of fasting state and tend to cancel the effect of postprandial absorption.
  • Major adverse reactions which may occur are diarrhea, nausea and vomiting.
  • Anti-Bacterials